DEVELOPMENT OF NEW ANTI-FELINE LEUKEMIA VIRUS DRUGS

新型抗猫白血病病毒药物的开发

• 批准号: 3489639
• 负责人: John E. Heidrich
• 金额: $ 4.4万
• 依托单位: ALBUQUERQUE AVIAN CLINIC
• 依托单位国家: 美国
• 财政年份: 1992
• 资助国家: 美国
• 起止时间: 1992-06-01 至 1992-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3489639
• 关键词: antiviral agents; blood tests; bone marrow exam; cats; chemotherapy; clinical chemistry; disease /disorder model; drug adverse effect; drug design /synthesis /production; drug screening /evaluation; enzyme linked immunosorbent assay; epizootiology; feline leukemia /sarcoma virus; pharmacology; veterinary medicine

DESCRIPTION: (Adapted from the Applicant's Abstract). In collaborative studies with investigators at the University of New Mexico School of Medicine, the Principal Investigator has obtained preliminary data on the antiviral properties of derivatives of the natural product gossypol. In particular, one derivative named GIL has shown promising activity in the treatment of domestic cats infected with feline leukemia virus (FeLV). Also noteworthy is the fact that GIL shows promising in vitro activity against the AIDS virus, HIV-1, suggesting that GIL and other derivatives of gossypol may have broad spectrum antiviral activities. The specific aim of this Phase I application is to conduct a controlled clinical study of the effectiveness of GIL against feline leukemia virus in infected cats. This phase of the research is designed: 1) to confirm the preliminary results with GIL, using a larger population of animals under controlled conditions; 2) to obtain clinical data pertaining to the toxicity of GIL.

描述：(改编自申请人的摘要)。在协作中 与新墨西哥大学学院的研究人员进行的研究 医学，首席调查员已经获得了关于 天然产物棉酚衍生物的抗病毒特性。在……里面 特别是，一种名为GIL的衍生品在 家猫感染猫白血病病毒(FeLV)的治疗。 同样值得注意的是，GIL在体外显示出良好的活性。 对抗艾滋病病毒，HIV-1，表明GIL和其他衍生品 棉酚可能具有广谱的抗病毒活性。 此第一阶段应用程序的具体目标是进行受控 GIL抗猫白血病病毒作用的临床研究 在受感染的猫身上。这一阶段的研究旨在：1)确认 GIL的初步结果，使用了更大数量的动物 在受控条件下；2)获得与以下有关的临床数据 GIL的毒性。